SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?
PRCT 31.91+1.9%Nov 7 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Douglas who wrote (228)8/6/1997 11:28:00 PM
From: Gerald Thomas   of 455
 
Unfortunately as far as I'm concerned Procept has PRO -2000
and that is pretty much it...
The other stuff with the cd1 and everything else isn't enough for me to take any interest in...

The repligen scenerio ...I don't know.
I'm having a hard time seeing the Paramount situation as anything other than financial support...

Unfortunately Paramount cannot buy them a working product..
I think all the financing while important has to be secondary to the product.

When I bought in Procept was testing PRO-2000 for hiv as a treatment...Years later they are still talking about PRO -2000 now for topical but they just have to get a grip and see if it works...
Years of drifting is why the stock price is where it is...

To be talking about next year and then maybe that not being efficacy
you just have to wonder what they could be thinking....

Unfortunately that is the way I see it and the financing
shouldn't hide their lack of action on the topical trial...

If they were to begin to mention efficacy in the phase 2 trial -Just Mentioning that would put the stock in play...

But now you ask what is the stock worth? NOT MUCH
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext